EGFR and lung carcinoma: Several ongoing T-cell engager studies in lung cancer include a variety of tumor-cell targets (e.g., EpCAM, B7-H6, Glypican-3, EGFR, among others), often with the T-cell engagement mechanism involving CD3 binding on the T-cell surface (89).